Understanding the role of tariquidar, a potent Pgp inhibitor, in combination trials with cytotoxic drugs: What is missing?

Affiliations

Comment

Nuggehally R Srinivas. Cancer Chemother Pharmacol. 2016 Nov.

. 2016 Nov;78(5):1097-1098.

doi: 10.1007/s00280-016-3044-4. Epub 2016 May 13.

¹ Suramus Bio, Drug Development, 29th Main, 10th Cross, J.P. Nagar I Phase, Bangalore, Karnataka, 560078, India. srini.suramus@yahoo.com.

No abstract available

Comment in

15-0600-Dr. Fox's response to letter to the editor.
Fox E, Balis FM. Fox E, et al. Cancer Chemother Pharmacol. 2016 Nov;78(5):1099-1100. doi: 10.1007/s00280-016-3162-z. Epub 2016 Oct 11. Cancer Chemother Pharmacol. 2016. PMID: 27730303 Free PMC article. No abstract available.

Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors.
Fox E, Widemann BC, Pastakia D, Chen CC, Yang SX, Cole D, Balis FM. Fox E, et al. Cancer Chemother Pharmacol. 2015 Dec;76(6):1273-83. doi: 10.1007/s00280-015-2845-1. Epub 2015 Oct 20. Cancer Chemother Pharmacol. 2015. PMID: 26486517 Free PMC article. Clinical Trial.